Please Give us your valued Feedback to serve you better.  Edition #2 March 30th - 2011 For a Browser View. Click Here
Featured Article
At the end of this November, Pfizer Inc., the world’s largest Pharmaceutical company stands to lose a revenue stream of $10 billion a year when its patent on Lipitor (blockbuster cholesterol drug) expires. For Pfizer, replacing Lipitor is a huge challenge as the product used to account for more than 20 per cent of the company’s sales till last year. Now, the brand will begin facing generic competition from end of 2011. Over the past few years, Pfizer has been trying its level best to launch at least two potential blockbusters in place of Lipitor but failed in late-stage human trials. One was a breast cancer drug, Sutent and another a lung cancer drug. The year 2011 also marks the end of an era for the global pharmaceutical industry, which has been long relying on blockbuster drugs to keep it financially healthy. It is expected that nine of industry’s 10 blockbusters will be going off patent and face generic competition within next five years. What is disturbing this high profit making industry today is the prospects of an estimated 30 billion loss in revenue over the next ten years on account of expiry of patents. And there is very few promising molecules to replace these blockbusters in the pipeline.
An important reason for the declining number of blockbusters for the global pharma companies is the tightened regulatory hurdles placed by the US FDA and the European authorities in clearing new drugs. The number of new drugs approved for marketing has been steadily falling despite rising public and private spending for research and development. Approval of new treatments by the US FDA has dropped from an average of more than 35 a year in the mid-1990s to just 20 in 2009. For the regulatory authorities, clearances have to be tight as increasing number of drugs are failing in the market after the marketing approvals are given. At least a dozen drugs had to be recalled from the global markets during the last 5 years. It is certainly a poor reflection on the integrity of the regulatory authorities. All these put enormous pressure on international pharmaceutical industry to reinvent itself and shed its dependence on blockbuster drugs. It is not very clear how they will do it. However, the primary concern for the companies now is to cut huge costs of R&D and protect the bottom line. Some are thus turning away from in house drug development and joining with universities and other companies to create new and more targeted medicines. By doing this, pharma companies hope to cut as much as 30 per cent of the R&D cost in the next few years. Cut in R&D costs is not probably the right answer for the current crisis as it kills the very progress and advancement of this industry. What is to be addressed urgently is how to raise the productivity in R&D in the pharmaceutical industry.
Source :- Click here.
|
In This Issue
Global @ Podium
Novartis completes acquisition of majority stake in Zhejiang Tianyuan
Indian @ Podium
Events @ Podium
InterpheX Expo , USA
Also-In-The-News@ Podium
|
The Japanese drugmaker has received approval from the European Commission for Halaven (eribulin) for the treatment of patients with locally advanced breast cancer who have progressed after at least two chemotherapy regimens.
Novartis completed the transaction to acquire an 85 percent stake in the Chinese vaccines company Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd. This acquisition provides Novartis with an expanded presence in the Chinese vaccines market and...
I urge you to extend the supplemental agreement you already have in place with the state and provide additional pricing considerations that will translate into a cost savings for the program. Only by a shared responsibility to sustain this program can we ensure ADAP will serve all the people who rely on it.
The Indian health sciences industry has witnessed a Budget without much mention. Whilst there were a few positives for this industry, the industry wishlist largely remained unaddressed.
Daiichi Sankyo Company and Ranbaxy Laboratories announced the start of a synergistic initiative to leverage Ranbaxy’s presence in Singapore to market innovative products originally discovered by Daiichi Sankyo. | IMPORTANT :- Please click on this link for an event brief. : Click Here
27th -28th April, 2011
Venue:- ITC Maratha
Mumbai ,India
Details :- Click Here
28th -31st March, 2011
Venue:- Marina Bay,sands
Singapore city,Singapore
Details :- Click Here
29th - 31st March,2011
Venue :- Jacob Javits,Covnention Centre
New York, USA
Details :- Click Here
22nd - 24th March,2011
Venue :- Dubai international Convention Centre
Dubai, UAE
Details :- Click Here
12th-18th May,2011
Venue :- Dubai international Convention Centre
Dusseldorf, Germany
Details :- Click Here |
With the industry still opposed to the idea of implementing barcode in the proposed format for pharmaceutical exports from July 1, the Commerce Ministry is likely to relax the norms and implement it in a phased manner, depending on the suggestions from the industry gathered by March 31.
On the 100th International Women’s Day, LifeCell International, pioneers in stem cell banking, launched LifeCell Femme — menstrual blood stem cell banking service in India.Menstrual blood banking has been pioneered by Cryo-Cell International..
Have you ever wondered why many of our nearly 800 MPs and 4000+ MLAs from rural constituencies rush to establish educational trusts but show no interest in addressing the crying need for rural hospitals?
Prof : Ganesh Devy , a celebrated Linguist and Sahitya Akademi award winner, whose contribution to the People's Linguistic Survey of India has been indispensible. PLSI is an unofficial survey that has nearly 1,200 volunteers and is taking into account ..
Nato says it has agreed to take over responsibility from the US for enforcing the no-fly zone over Libya. Secretary General Anders Fogh Rasmussen said talks would continue on giving Nato a "broader responsibility", with a decision possible in the coming days.
Fears of radiation contamination from a crippled Japanese nuclear power plant have prompted governments around the world to either halt food imports from Japan, or step up tests, nearly two weeks after a devastating earthquake and tsunami.
|
|
| |
|
No comments:
Post a Comment